Picture of ImmuPharma logo

IMM ImmuPharma News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapMomentum Trap

REG - AIM - AIM Notice - 12/09/2023

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230912:nRSL0601Ma&default-theme=true

RNS Number : 0601M  AIM  12 September 2023

NOTICE

 

12/09/2023 - 08:00

 

The London Stock Exchange admits the following securities to trading on AIM:

 

 E-THERAPEUTICS PLC
 1,150,000  ORDINARY SHARES OF 0.1P EACH, FULLY PAID  (B2823H9)(GB00B2823H99)

 

 EUROPEAN METALS HOLDINGS LIMITED
 400,000  ORDINARY SHARES OF NO PAR VALUE; FULLY PAID (DI)  (BD03B84)(VGG3191T1021)

 

 GALILEO RESOURCES PLC
 2,500,000  ORDINARY SHARES OF 0.1P EACH, FULLY PAID  (B115T14)(GB00B115T142)

 

 IDOX PLC
 66,666  ORDINARY SHARES OF 1P EACH, FULLY PAID  (0299819)(GB0002998192)

 

 IMMUPHARMA PLC
 6,534,150  ORDINARY SHARES OF 1P EACH, FULLY PAID  (3371101)(GB0033711010)

 

If you have any queries or require further information, please contact Market
Operations on 020 7797 4310.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AMOBSGDCIXBDGXB

Recent news on ImmuPharma

See all news